<DOC>
	<DOC>NCT02166151</DOC>
	<brief_summary>The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.</brief_summary>
	<brief_title>Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>diagnosis of chronic idiopathic urticaria for 3 months failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin physical or cholinergic urticaria past treatment in Omalizumab i nprevious year parasitic infection malignancy in last 5 years known sensitivity to Omalizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>